OncoMatch/Clinical Trials/NCT06084962
A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
Is NCT06084962 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies DeepTag-GPRC5D Targeted CAR T-cells for relapse/refractory multiple myeloma.
Treatment: DeepTag-GPRC5D Targeted CAR T-cells — Clinical Trial for the safety and efficacy of DeepTag-GPRC5D targeted CAR-T cells therapy for refractory/relapsed multiple myeloma
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
including chemotherapy based on proteasome inhibitors (PIs)
Must have received: immunomodulatory agent
immunomodulatory agents (IMiDs)
Must have received: CD38 antibody
CD38 antibody
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: within 8 weeks before screening
Patients who received autologous hematopoietic stem cell transplantation (ASCT) within 8 weeks before screening
Cannot have received: allogeneic stem cell therapy
Patients received allogeneic stem cell therapy
Cannot have received: anti-cancer chemotherapy or other medications
Exception: within 2 weeks before screening
Patients who received anti-cancer chemotherapy or other medications within 2 weeks before screening
Lab requirements
Blood counts
Lymphocyte count > 0.3×10e9/L; Neutrophils ≥ 0.5×10e9/L; Hemoglobin ≥ 60g/L; Platelet ≥ 30×10e9/L
Kidney function
Creatinine > 2.5 mg/dl [excluded]
Liver function
ALT / AST > 3 times of normal amounts, or bilirubin > 2.0 mg/dl [excluded]
Cardiac function
Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past [excluded]
The blood routine meets the following standards: Lymphocyte count > 0.3×10e9/L; Neutrophils ≥ 0.5×10e9/L; Hemoglobin ≥ 60g/L; Platelet ≥ 30×10e9/L; Creatinine > 2.5mg/dl, or ALT / AST > 3 times of normal amounts, or bilirubin > 2.0 mg/dl [excluded]; Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify